Browse DGKZ

Summary
SymbolDGKZ
Namediacylglycerol kinase, zeta
Aliases hDGKzeta; DGK-ZETA; diacylglycerol kinase, zeta 104kDa; DAG kinase zeta; diglyceride kinase zeta; Diacylglyc ......
Chromosomal Location11p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Nucleus Cell membrane
Domain PF12796 Ankyrin repeats (3 copies)
PF00130 Phorbol esters/diacylglycerol binding domain (C1 domain)
PF00609 Diacylglycerol kinase accessory domain
PF00781 Diacylglycerol kinase catalytic domain
Function

Displays a strong preference for 1,2-diacylglycerols over 1,3-diacylglycerols, but lacks substrate specificity among molecular species of long chain diacylglycerols. Isoform 2 but not isoform 1 regulates RASGRP1 activity.

> Gene Ontology
 
Biological Process GO:0006638 neutral lipid metabolic process
GO:0006639 acylglycerol metabolic process
GO:0007205 protein kinase C-activating G-protein coupled receptor signaling pathway
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0030168 platelet activation
GO:0030258 lipid modification
GO:0046339 diacylglycerol metabolic process
GO:0046486 glycerolipid metabolic process
GO:0046834 lipid phosphorylation
GO:0050817 coagulation
GO:0050878 regulation of body fluid levels
Molecular Function GO:0004143 diacylglycerol kinase activity
Cellular Component GO:0030027 lamellipodium
GO:0031252 cell leading edge
> KEGG and Reactome Pathway
 
KEGG hsa04070 Phosphatidylinositol signaling system
hsa00561 Glycerolipid metabolism
hsa00564 Glycerophospholipid metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-114508: Effects of PIP2 hydrolysis
R-HSA-416476: G alpha (q) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-109582: Hemostasis
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
Summary
SymbolDGKZ
Namediacylglycerol kinase, zeta
Aliases hDGKzeta; DGK-ZETA; diacylglycerol kinase, zeta 104kDa; DAG kinase zeta; diglyceride kinase zeta; Diacylglyc ......
Chromosomal Location11p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between DGKZ and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolDGKZ
Namediacylglycerol kinase, zeta
Aliases hDGKzeta; DGK-ZETA; diacylglycerol kinase, zeta 104kDa; DAG kinase zeta; diglyceride kinase zeta; Diacylglyc ......
Chromosomal Location11p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of DGKZ in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen Total # shRNA with >= 4-fold: 1 Resistant to T-cell proliferation
24476824shRNAmelanomaB16Secondary screen Total # shRNA with >= 4-fold: 6 Resistant to T-cell proliferation
Summary
SymbolDGKZ
Namediacylglycerol kinase, zeta
Aliases hDGKzeta; DGK-ZETA; diacylglycerol kinase, zeta 104kDa; DAG kinase zeta; diglyceride kinase zeta; Diacylglyc ......
Chromosomal Location11p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of DGKZ in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0520.832
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1810.929
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.220.88
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2890.41
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2490.92
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3410.915
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1910.591
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.260.863
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1190.943
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.6260.698
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.3680.88
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1160.172
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of DGKZ in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.3014.30.196
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103200201
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.407.40.0709
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.407.40.096
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.907.90.26
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolDGKZ
Namediacylglycerol kinase, zeta
Aliases hDGKzeta; DGK-ZETA; diacylglycerol kinase, zeta 104kDa; DAG kinase zeta; diglyceride kinase zeta; Diacylglyc ......
Chromosomal Location11p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of DGKZ. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolDGKZ
Namediacylglycerol kinase, zeta
Aliases hDGKzeta; DGK-ZETA; diacylglycerol kinase, zeta 104kDa; DAG kinase zeta; diglyceride kinase zeta; Diacylglyc ......
Chromosomal Location11p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of DGKZ. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by DGKZ.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolDGKZ
Namediacylglycerol kinase, zeta
Aliases hDGKzeta; DGK-ZETA; diacylglycerol kinase, zeta 104kDa; DAG kinase zeta; diglyceride kinase zeta; Diacylglyc ......
Chromosomal Location11p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of DGKZ. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolDGKZ
Namediacylglycerol kinase, zeta
Aliases hDGKzeta; DGK-ZETA; diacylglycerol kinase, zeta 104kDa; DAG kinase zeta; diglyceride kinase zeta; Diacylglyc ......
Chromosomal Location11p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of DGKZ expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolDGKZ
Namediacylglycerol kinase, zeta
Aliases hDGKzeta; DGK-ZETA; diacylglycerol kinase, zeta 104kDa; DAG kinase zeta; diglyceride kinase zeta; Diacylglyc ......
Chromosomal Location11p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between DGKZ and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolDGKZ
Namediacylglycerol kinase, zeta
Aliases hDGKzeta; DGK-ZETA; diacylglycerol kinase, zeta 104kDa; DAG kinase zeta; diglyceride kinase zeta; Diacylglyc ......
Chromosomal Location11p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting DGKZ collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.